Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.
Bluejay Diagnostics develops rapid, near-patient diagnostic testing for critical care settings through its Symphony™ platform. The company’s lead product candidate, the Symphony™ IL-6 Test, is designed to measure interleukin-6 for sepsis triage, patient monitoring, and risk assessment, with sample-to-result testing described at approximately 20 minutes.
Bluejay news commonly covers SYMON clinical studies, IL-6 biomarker data, conference presentations, manufacturing readiness for Symphony cartridges, antibody production for test components, and regulatory preparation. Company updates also include financing activity, warrant exercises, reverse stock splits, and other capitalization matters. The Symphony System does not yet have U.S. FDA regulatory clearance and requires authorization before it can be marketed as a diagnostic product in the United States.
Bluejay Diagnostics announced a 1-for-8 reverse stock split effective June 20, 2024. This will reduce outstanding shares from approximately 4.5 million to around 564,000, with no change in par value. Fractional shares will be compensated in cash. The stock will trade under the same symbol, BJDX, but with a new CUSIP number. The reverse split affects all shareholders uniformly, preserving their percentage ownership except for fractional share adjustments. The transfer agent for this process is Continental Stock Transfer & Trust Company. Bluejay focuses on rapid diagnostics to improve patient outcomes in critical care settings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.